Form4insider filings, from the source

SEC Form 4 · accession 0000899243-16-028188

Clovis Oncology, Inc. · CLVS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Daniel W Muehl
Officer — See Remarks
Period of report
Aug 25, 2016
Accepted (ET)
Aug 29, 2016 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F1$22.73Aug 25, 2016A37,500A—Aug 25, 2026Common Stock37,50037,500D
Restricted Stock UnitsF2,F3—Aug 25, 2016A8,750A——Common Stock8,7508,750D
Stock Option (right to buy)F4,F5$84.83holding————Jul 6, 2025Common Stock35,00035,000D
Stock Option (right to buy)F4,F5$19.37holding————Mar 1, 2026Common Stock7,5007,500D
Restricted Stock UnitsF2,F6,F7—holding—————Common Stock2,5002,500D

Explanation of responses

Remarks

Vice President of Finance, Principal Financial Officer and Principal Accounting Officer